MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity

Cancer Letters

Volumn 331, Issue 1, 2013, Pages 92-98

  Rochais, Christophe ^a   Cresteil, Thierry ^b   Perri, Vittoria ^a   Jouanne, Marie ^a   Lesnard, Aurélien ^a   Rault, Sylvain ^a   Dallemagne, Patrick ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b CNRS   (France)

Author keywords

FLT3; FLT3 ITD; Tripentone; Tubulin polymerization

Indexed keywords

ANTINEOPLASTIC AGENT; FLT3 ITD KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MR 22388; PROTEIN TYROSINE KINASE; TUBULIN; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR FLT3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; KARYOTYPE; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; PROTEIN POLYMERIZATION INHIBITION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRROLIZIDINE ALKALOIDS; TANDEM REPEAT SEQUENCES; TUBULIN; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 84873523119     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.017     Document Type: Article

References (16)

1. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
2. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Gari M.A., Peake I.R., Rees D.C., Vandenberghe E.A., Winship P.R., Reilly J.T. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 2000, 111:190-195.
3. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., Asou N., Kuriyama K., Jinnai I., Shimazaki C., Akiyama H., Saito K., Oh H., Motoji T., Omoto E., Saito H., Ohno R., Ueda R. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
4. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., Walker H., Wheatley K., Bowen D.T., Burnett A.K., Goldstone A.H., Linch D.C. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
5. Fröhling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Döhner H., Döhner K. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100. 4372-4280.
6. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., Carrol A.J., Mrózek K., Vardiman J.W., George S.L., Kolitz J.E., Larson R.A., Bloomfield C.D., Caligiuri M.A. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001, 61:7233-7239.
7. Kiyoi H., Ohno R., Ueda R., Saito H., Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21:2555-2563.
8. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J., Saxena K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 2004, 13:169-178.
9. Ozeki K., Kiyoi H., Hirose Y., Iwai M., Ninomiya M., Kodera Y., Miyawaki S., Kuriyama K., Shimazaki C., Akiyama H., Nishimura M., Motoji T., Shinagawa K., Takeshita A., Ueda R., Ohno R., Emi N., Naoe T. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004, 103:1901-1908.
10. Pemmeraju N., Kantarjian H., Ravandi F., Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia. The start of an era. Cancer 2011, 10.1002/cncr.25908.
11. Lisowski V., Léonce S., Kraus-Berthier L., Sopkova-de Oliveira Santos J., Pierré A., Atassi G., Caignard D.-H., Renard P., Rault S. Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J. Med. Chem. 2004, 47:1448-1464.
12. Zavala F., Guenard D., Robin J.P., Brown E. Structure-antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (+/-) isodeoxypodophyllotoxin. J. Med. Chem. 1980, 23:596-599.
13. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
14. Jacnike R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 1998, 273:9357-9360.
15. Chao Q., Sprankle K.G., Grotzfeld R.M., Lai A.G., Carter T.A., Velasco A.-M., Gunawardane R.N., Cramer M.D., Gardner M.F., James J., Zarrinkar P.P., Patel H.K., Bhagwat S.S. Identification of N-(5-tert-Butylisoxazol-3-yl)-N0-{4- [7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-Like Tyrosine Kinase-3 (FLT3) inhibitor. J. Med. Chem. 2009, 52:7808-7816.
16. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., Gardner M.F., Brigham D., Belli B., Karaman M.W., Pratz K.W., Pallares G., Chao Q., Sprankle K.G., Patel H.K., Armstrong R.C., James J., Bhagwat S.S. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia. Blood 2009, 114:2984-2992.